Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
IBER.WS
IBER.WS was delisted on the 15th of February, 2023.
33 hedge funds and large institutions have $1.78M invested in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
13% less funds holding
Funds holding: 38 → 33 (-5)
18% less capital invested
Capital invested by funds: $2.19M → $1.78M (-$404K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETH
Exos TFP Holdings
New York
|
+$2K |
| 2 |
CS
Clear Street
New York
|
+$276 |
| 3 |
EFI
EHP Funds Inc
Toronto,
Canada
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$134K |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$5.74K |
| 3 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4K |
| 5 |
AGM
Alpine Global Management
New York
|
-$1.57K |
IBER.WS Hedge Fund Activity: Q4 2022 in Review
33 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q4 2022, worth a combined $1.78M — down 18% from $2.19M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IBER.WS and 0 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Exos TFP Holdings, adding an estimated $2K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $134K sold.
- 33 institutional investors held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q4 2022, down from 38 in Q3 2022.
- Funds reported $1.78M of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q4 2022, down 18% quarter-over-quarter.
- 0 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q4 2022 and 5 closed out, a net change of -5 holders.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share buyer in Q4 2022 was Exos TFP Holdings, an estimated $2K added.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q4 2022 was Boothbay Fund Management, an estimated $134K sold.
Based on aggregated 13F filings for Q4 2022.